PineBridge Investments’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.6M | Buy |
55,100
+52,199
| +1,799% | +$24.3M | 0.21% | 98 |
|
|
2025
Q4 | $1.32M | Buy |
+2,901
| New | +$1.25M | 0.01% | 382 |
|
|
2025
Q3 | – | Sell |
-562
| Closed | -$250K | – | 598 |
|
|
2025
Q2 | $250K | Sell |
562
-13,634
| -96% | -$6.28M | ﹤0.01% | 542 |
|
|
2025
Q1 | $6.88M | Sell |
14,196
-252
| -2% | -$117K | 0.05% | 270 |
|
|
2024
Q4 | $5.82M | Sell |
14,448
-39,692
| -73% | -$18.4M | 0.04% | 285 |
|
|
2024
Q3 | $25.2M | Sell |
54,140
-26,561
| -33% | -$12.8M | 0.19% | 126 |
|
|
2024
Q2 | $37.8M | Sell |
80,701
-943
| -1% | -$409K | 0.31% | 76 |
|
|
2024
Q1 | $34.1M | Buy |
81,644
+8,242
| +11% | +$3.48M | 0.27% | 79 |
|
|
2023
Q4 | $29.9M | Sell |
73,402
-41,516
| -36% | -$15.3M | 0.28% | 85 |
|
|
2023
Q3 | $40M | Sell |
114,918
-42,193
| -27% | -$14.8M | 0.44% | 49 |
|
|
2023
Q2 | $55.3M | Sell |
157,111
-29,717
| -16% | -$10M | 0.6% | 28 |
|
|
2023
Q1 | $58.9M | Buy |
186,828
+23,056
| +14% | +$6.92M | 0.66% | 31 |
|
|
2022
Q4 | $47.3M | Buy |
163,772
+2,683
| +2% | +$818K | 0.57% | 40 |
|
|
2022
Q3 | $46.6M | Buy |
161,089
+54,590
| +51% | +$15.7M | 0.6% | 30 |
|
|
2022
Q2 | $30M | Buy |
106,499
+106,241
| +41,179% | +$28.4M | 0.38% | 55 |
|
|
2022
Q1 | $67K | Sell |
258
-20,765
| -99% | -$4.93M | ﹤0.01% | 563 |
|
|
2021
Q4 | $4.62M | Sell |
21,023
-94,562
| -82% | -$18.4M | 0.05% | 297 |
|
|
2021
Q3 | $21M | Buy |
115,585
+5,280
| +5% | +$1.03M | 0.25% | 107 |
|
|
2021
Q2 | $22.2M | Buy |
110,305
+34,483
| +45% | +$7.21M | 0.26% | 95 |
|
|
2021
Q1 | $16.3M | Buy |
75,822
+15,648
| +26% | +$3.44M | 0.21% | 125 |
|
|
2020
Q4 | $14.2M | Buy |
60,174
+3,380
| +6% | +$776K | 0.22% | 112 |
|
|
2020
Q3 | $15.5M | Buy |
56,794
+7,249
| +15% | +$2M | 0.27% | 94 |
|
|
2020
Q2 | $14.4M | Buy |
49,545
+24,096
| +95% | +$6.53M | 0.28% | 87 |
|
|
2020
Q1 | $6.06M | Buy |
25,449
+25,243
| +12,254% | +$5.79M | 0.14% | 181 |
|
|
2019
Q4 | $45K | Sell |
206
-2,214
| -91% | -$448K | ﹤0.01% | 936 |
|
|
2019
Q3 | $410K | Buy |
2,420
+1,653
| +216% | +$292K | 0.01% | 864 |
|
|
2019
Q2 | $141K | Buy |
+767
| New | +$134K | ﹤0.01% | 801 |
|
|
2018
Q4 | – | Sell |
-186
| Closed | -$36K | – | 1130 |
|
|
2018
Q3 | $36K | Sell |
186
-119
| -39% | -$21.2K | ﹤0.01% | 1005 |
|
|
2018
Q2 | $52K | Sell |
305
-1,135
| -79% | -$176K | ﹤0.01% | 987 |
|
|
2018
Q1 | $235K | Sell |
1,440
-3,129
| -68% | -$511K | 0.01% | 865 |
|
|
2017
Q4 | $685K | Buy |
4,569
+4,415
| +2,867% | +$654K | 0.02% | 695 |
|
|
2017
Q3 | $23K | Buy |
+154
| New | +$23.2K | ﹤0.01% | 1117 |
|
|
2016
Q3 | – | Sell |
-309
| Closed | -$27K | – | 1175 |
|
|
2016
Q2 | $27K | Buy |
309
+127
| +70% | +$11K | ﹤0.01% | 1046 |
|
|
2016
Q1 | $14K | Buy |
182
+17
| +10% | +$1.54K | ﹤0.01% | 1080 |
|
|
2015
Q4 | $21K | Buy |
+165
| New | +$19.9K | ﹤0.01% | 1051 |
|
|
2015
Q2 | – | Sell |
-89
| Closed | -$10K | – | 1148 |
|
|
2015
Q1 | $10K | Sell |
89
-17,935
| -100% | -$2.15M | ﹤0.01% | 1078 |
|
|
2014
Q4 | $2.14M | Buy |
18,024
+1,189
| +7% | +$134K | 0.08% | 214 |
|
|
2014
Q3 | $1.89M | Sell |
16,835
-46,794
| -74% | -$4.46M | 0.08% | 224 |
|
|
2014
Q2 | $6.03M | Sell |
63,629
-11,280
| -15% | -$791K | 0.24% | 119 |
|
|
2014
Q1 | $5.3M | Buy |
74,909
+29,629
| +65% | +$2.35M | 0.17% | 141 |
|
|
2013
Q4 | $3.36M | Buy |
+45,280
| New | +$3.15M | 0.1% | 180 |
|
Other funds holding VRTX
VCM
VPM
PineBridge Investments's VRTX Position: Q1 2026 in Review
PineBridge Investments increased its Vertex Pharmaceuticals (VRTX) stake by 1,799% in Q1 2026, buying an estimated $24.3M and bringing the position to 55,100 shares worth $24.6M. The position accounts for 0.21% of the portfolio, ranked #98.
PineBridge Investments first reported a position in VRTX in Q4 2013 and has held it in 41 quarters since. The position peaked at $58.9M in Q1 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- PineBridge Investments held 55,100 shares of Vertex Pharmaceuticals worth $24.6M as of Q1 2026.
- PineBridge Investments bought 52,199 Vertex Pharmaceuticals shares in Q1 2026, an estimated $24.3M.
- Vertex Pharmaceuticals made up 0.21% of PineBridge Investments's portfolio in Q1 2026, its #98 holding.
- PineBridge Investments first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 41 quarters since.
- PineBridge Investments's Vertex Pharmaceuticals position peaked at $58.9M in Q1 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on PineBridge Investments's 13F filing for Q1 2026, filed 14 May 2026.